Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.76 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 6/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19466752 | 0.90 | RET (0.61) | RETAAK1PIM1PIM2CSNK2A1 | |
| SCHEMBL29660320 | 0.89 | RET (0.75) | RETAAK1PIM1PIM2KDR | |
| SCHEMBL19467191 | 0.88 | RET (0.83) | RETPIM1PIM2KDR | |
| SCHEMBL29660318 | 0.87 | RET (0.73) | RETAAK1PIM1PIM2KDR | |
| SCHEMBL15280689 | 0.81 | RET (0.48) | RETAAK1PIM1PIM2CSNK2A1 | |
| SCHEMBL15261797 | 0.80 | RET (0.49) | RETAAK1PIM1PIM2 | |
| SCHEMBL19466818 | 0.80 | RET (0.61) | RETPIM1PIM2KDR | |
| SCHEMBL29660257 | 0.79 | FYN (0.49) | RETAAK1PIM1PIM2CSNK2A1 | |
| SCHEMBL19467181 | 0.79 | RET (0.61) | RETPIM1PIM2KDR | |
| SCHEMBL31441708 | 0.78 | RET (0.47) | RETAAK1PIM1PIM2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | OXFORD FINANCE LLC | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666575-B2 | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections | IRAK1, SARS1, IRAK2 | RET 755/4885AAK1 4/4885PIM1 154/4885 |
| US-20220096481-A1 | PYRAZOLO[1,5]PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE TO TREAT VIRAL INFECTIONS | IRAK1, SARS1, IRAK2 | RET 755/4885AAK1 4/4885PIM1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.